We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+4.18%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$13.8M
Cap. Flow
+$18M
Cap. Flow %
5.13%
Top 10 Hldgs %
37.4%
Holding
88
New
31
Increased
19
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$9.29M
2
DHR icon
Danaher
DHR
+$9.16M
3
ZBH icon
Zimmer Biomet
ZBH
+$8.78M
4
NTLA icon
Intellia Therapeutics
NTLA
+$7.38M
5
MRK icon
Merck
MRK
+$6.96M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$8.76M
2
LLY icon
Eli Lilly
LLY
+$8.44M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.37M
4
NVRO
NEVRO CORP.
NVRO
+$7.83M
5
ABBV icon
AbbVie
ABBV
+$7.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.97%
2 Energy 3%
3 Industrials 0.97%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
51
Replimune Group
REPL
$1.15B
$2.17M 0.62%
71,000
+23,500
+49% +$880K
ALLO icon
52
Allogene Therapeutics
ALLO
$732M
$2.12M 0.61%
+60,000
New +$2.02M
RLAY icon
53
Relay Therapeutics
RLAY
$4.38B
$2.07M 0.59%
+60,000
New +$2.6M
AVTX icon
54
Avalo Therapeutics
AVTX
$1.04B
$1.81M 0.52%
+208
New +$1.97M
ZNTL icon
55
Zentalis Pharmaceuticals
ZNTL
$295M
$1.74M 0.5%
+40,000
New +$1.72M
KURA icon
56
Kura Oncology
KURA
$882M
$1.7M 0.48%
60,000
-35,000
-37% -$1.11M
CVS icon
57
CVS Health
CVS
$120B
$1.5M 0.43%
20,000
-80,000
-80% -$5.83M
MYOV
58
DELISTED
Myovant Sciences Ltd.
MYOV
$1.34M 0.38%
65,000
+15,000
+30% +$341K
SWAV
59
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$1.3M 0.37%
10,000
-25,000
-71% -$3M
KDMN
60
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.17M 0.33%
+300,000
New +$1.37M
RARE icon
61
Ultragenyx Pharmaceutical
RARE
$2.66B
$1.14M 0.33%
+10,000
New +$1.36M
ALEC icon
62
Alector
ALEC
$233M
$1.11M 0.32%
55,000
-110,000
-67% -$1.97M
MSON
63
DELISTED
Misonix Inc
MSON
$882K 0.25%
+45,000
New +$751K
DNTH icon
64
Dianthus Therapeutics
DNTH
$6.07B
$770K 0.22%
+4,063
New +$684K
ARDX icon
65
Ardelyx
ARDX
$1.02B
$629K 0.18%
+95,000
New +$652K
KPTI icon
66
Karyopharm Therapeutics
KPTI
$47.6M
$526K 0.15%
3,333
-3,334
-50% -$702K
LBPH
67
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$491K 0.14%
+30,000
New +$490K
TVTX icon
68
Travere Therapeutics
TVTX
$5.68B
$375K 0.11%
+15,000
New +$414K
KZR
69
DELISTED
Kezar Life Sciences
KZR
$119K 0.03%
+2,000
New +$117K
ABBV icon
70
AbbVie
ABBV
$442B
– –
-70,000
Closed -$7.5M
ABT icon
71
Abbott
ABT
$190B
– –
-80,000
Closed -$8.76M
ARWR icon
72
Arrowhead Research
ARWR
$12.6B
– –
-50,000
Closed -$3.84M
AVTR icon
73
Avantor
AVTR
$9.31B
– –
-200,000
Closed -$5.63M
BIIB icon
74
Biogen
BIIB
$30.1B
– –
-10,000
Closed -$2.45M
COR icon
75
Cencora
COR
$63.7B
– –
-70,000
Closed -$6.84M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Integral Health Asset Management held 88 positions worth $350M, up 4.1% from $336M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Integral Health Asset Management deployed $18M of net new capital in Q1 2021, opening 31 new positions and adding to 19 existing holdings. Its largest new stake was Centene: 150,000 shares worth $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was NEVRO CORP., an estimated $7.83M trimmed.

  • Integral Health Asset Management's largest Q1 2021 buy was Centene: 150,000 shares worth $9.59M.
  • Integral Health Asset Management added most to Intellia Therapeutics in Q1 2021, an estimated $7.38M increase.
  • Integral Health Asset Management's biggest Q1 2021 reduction was NEVRO CORP., cutting an estimated $7.83M.
  • Integral Health Asset Management fully exited Abbott in Q1 2021, selling an estimated $8.76M.
  • Integral Health Asset Management's ten largest holdings make up 37% of its $350M portfolio in Q1 2021.
  • Integral Health Asset Management opened 31 new positions and closed 19 in Q1 2021.
  • Integral Health Asset Management's portfolio value rose 4.1% quarter-over-quarter to $350M.

Based on Integral Health Asset Management's 13F filing for Q1 2021, filed 10 May 2021.